poisar

Stocks · News reference

Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Karyopharm Therapeutics Inc. (KPTI)

    Filed: 2026-11-03 AccNo: 0001193125-26-444164 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 1.03: Bankruptcy or Receivership Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits